Skip to main content
. 2021 May 8;28(3):1761–1772. doi: 10.3390/curroncol28030164

Table 4.

Phase II: best overall response and clinical benefit rate.

BEST OVERALL RESPONSE ARM A (Nab-FOLFIRI) ARM B (Nab-FOLFOX)
N % N %
CR 0 0 0 0
PR 13 31 13 31
SD 16 38 17 40
PD 11 26 7 17
Not assessed 2 5 5 12
CLINICAL BENEFIT RATE
CR + PR + SD 29 69 30 71
Other 13 31 12 29